Warren J S
Department of Pathology, University of Michigan Medical School, Ann Arbor 48109-0602.
Am J Pathol. 1992 Sep;141(3):551-60.
Intrapulmonary interleukin-1 beta (IL-1 beta) participates in the pathogenesis of acute IgG immune-complex alveolitis through a mechanism involving neutrophil recruitment. We have examined the relationship between intrapulmonary IL-1 beta and locally produced platelet-activating factor (PAF) in the development of acute alveolitis. Instillation of IgG anti-bovine albumin into the lungs of rats, followed immediately by intravenous infusion of bovine serum albumin (BSA), resulted in acute neutrophil-mediated lung injury. Development of IgG immune-complex lung injury was accompanied by three- and five-fold increases in bronchoalveolar lavage (BAL) fluid and whole lung PAF levels, respectively. Intratracheal administration of the PAF antagonists, WEB-2086 (Boehringer) or L-652,731 (Merck, Sharpe, and Dohme, Rahway, NJ), reduced pulmonary vascular leakage. Neutralization of intrapulmonary IL-1 activity with anti-IL-1 beta antibodies reduced pulmonary vascular permeability and whole lung PAF levels. Morphometric analysis and whole lung myeloperoxidase measurements revealed a differential effect between the PAF antagonists and anti-IL-1 beta with respect to pulmonary neutrophil recruitment. Intratracheal instillation of anti-IL-1 beta retarded net pulmonary neutrophil recruitment while the PAF antagonists retarded migration of neutrophils from the interstitial/vascular compartments into the alveolar compartment. Intratracheal instillation of anti-IL-1 beta plus L-652,731 resulted in reduction in lung vascular permeability and retarded net pulmonary neutrophil recruitment. No additive effect was observed. Stimulation of isolated mouse alveolar macrophages with recombinant murine IL-1 beta or IL-1 alpha resulted in rapid, dose-dependent, and cell concentration-dependent increases in PAF secretion. These data suggest that intrapulmonary IL-1 beta amplifies local PAF production and that IL-1 beta and PAF modulate different aspects of pulmonary neutrophil recruitment.
肺内白细胞介素-1β(IL-1β)通过涉及中性粒细胞募集的机制参与急性IgG免疫复合物肺泡炎的发病过程。我们研究了急性肺泡炎发展过程中肺内IL-1β与局部产生的血小板活化因子(PAF)之间的关系。将抗牛白蛋白IgG注入大鼠肺内,随后立即静脉输注牛血清白蛋白(BSA),导致急性中性粒细胞介导的肺损伤。IgG免疫复合物肺损伤的发展分别伴随着支气管肺泡灌洗(BAL)液和全肺PAF水平增加3倍和5倍。气管内给予PAF拮抗剂WEB-2086(勃林格公司)或L-652,731(默克公司,新泽西州拉威市)可减少肺血管渗漏。用抗IL-1β抗体中和肺内IL-1活性可降低肺血管通透性和全肺PAF水平。形态计量分析和全肺髓过氧化物酶测量显示,PAF拮抗剂和抗IL-1β在肺中性粒细胞募集中具有不同的作用。气管内滴注抗IL-1β可延缓肺中性粒细胞的净募集,而PAF拮抗剂可延缓中性粒细胞从间质/血管腔室向肺泡腔室的迁移。气管内滴注抗IL-1β加L-652,731可降低肺血管通透性并延缓肺中性粒细胞的净募集。未观察到相加效应。用重组鼠IL-1β或IL-1α刺激分离的小鼠肺泡巨噬细胞可导致PAF分泌迅速、剂量依赖性和细胞浓度依赖性增加。这些数据表明,肺内IL-1β可放大局部PAF的产生,并且IL-1β和PAF调节肺中性粒细胞募集的不同方面。